← Browse by Condition
Medical Condition

lung neoplasms

Total Trials
6
Recruiting Now
6
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for lung neoplasms sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

  • Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
  • Phase 1–4 studies from early safety trials to post-marketing surveillance
  • NIH, pharmaceutical sponsor, and academic medical center studies worldwide
  • AI-powered plain-language summary available for every trial listing

Frequently Asked Questions — lung neoplasms Clinical Trials

How many clinical trials are currently recruiting for lung neoplasms?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for lung neoplasms, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for lung neoplasms?
lung neoplasms research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a lung neoplasms clinical trial?
Eligibility criteria for lung neoplasms trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
National University Hospital, Singapore 1 trial
Shanghai Pulmonary Hospital, Shanghai, China 1 trial
The First Affiliated Hospital with Nanjing Medical University 1 trial
AstraZeneca 1 trial
National Taiwan University Hospital 1 trial

Recruiting Clinical Trials

NCT07358715
Recruiting

Liquid Biopsy-Based Pre-Screening to Streamline LDCT Lung Cancer Screening in High-Risk Individuals

Enrollment
140 pts
Location
Singapore
Sponsor
National University Hospital, ...
View Trial →
NCT06758700 Phase 2
Recruiting

Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer

Enrollment
15 pts
Location
China
Sponsor
Shanghai Pulmonary Hospital, S...
View Trial →
NCT04944563
Recruiting

Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field

Enrollment
1,120 pts
Location
China
Sponsor
The First Affiliated Hospital ...
View Trial →
NCT07109154
Recruiting

DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns

Enrollment
200 pts
Location
Brazil
Sponsor
AstraZeneca
View Trial →
NCT07436598
Recruiting

3D Virtual Resection for Predicting Lung Function in VATS

Enrollment
60 pts
Location
Taiwan
Sponsor
National Taiwan University Hos...
View Trial →
NCT01580982
Recruiting

Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer

Enrollment
500 pts
Location
United States
Sponsor
University of Colorado, Denver
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology